ALK and neoplasm: To explore possibility of targeted therapy, the tumor samples were subjected to genomic sequencing by using next-generation sequencing (NGS), and the results showed that this patient carried two ALK fusions simultaneously, EML4-ALK (V3) and CDK15-ALK (Fig. 2).